Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Biodexa Pharmaceuticals ( (BDRX) ) has issued an announcement.
On January 5, 2026, Biodexa Pharmaceuticals PLC appointed long-serving Group Financial Controller Fiona Sharp as its Chief Financial Officer, Corporate Secretary and a member of the Board of Directors, with the move disclosed in a filing dated January 6, 2026. She succeeds Stephen Stamp in the CFO and Corporate Secretary roles, while he remains Chief Executive Officer, and will serve as a director until the company’s 2026 annual general meeting. Sharp, a Chartered Certified Accountant with extensive financial leadership experience in healthcare and communications sectors, has no reported related-party ties or transactions with the company, underscoring a governance-led, continuity-focused leadership transition aimed at reinforcing Biodexa’s financial stewardship and board oversight for stakeholders.
The most recent analyst rating on (BDRX) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Biodexa Pharmaceuticals stock, see the BDRX Stock Forecast page.
Spark’s Take on BDRX Stock
According to Spark, TipRanks’ AI Analyst, BDRX is a Neutral.
The score is pressured primarily by weak financial performance (zero 2024 revenue, persistent losses, and significant ongoing cash burn) and bearish technicals (price well below key moving averages with negative MACD). Valuation does not provide a clear offset due to negative earnings and no dividend yield data.
To see Spark’s full report on BDRX stock, click here.
More about Biodexa Pharmaceuticals
Biodexa Pharmaceuticals PLC is a UK-based pharmaceutical company, listed in the United States as a foreign private issuer. The company operates in the life sciences sector and is subject to U.S. securities regulation, including filing obligations under the Securities Exchange Act of 1934, indicating an international capital markets focus.
Average Trading Volume: 1,110,782
Technical Sentiment Signal: Sell
Current Market Cap: $1.56M
For detailed information about BDRX stock, go to TipRanks’ Stock Analysis page.